Business

Elevation Pharmaceuticals, which is developing several inhalation products, has agreed to be acquired by Sunovion. Both boards have approved the deal. The agreement includes an upfront payment of $100 million and milestone payments for development… Read more . . .

A new research report titled “Global Markets for Asthma & COPD Drugs” from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38… Read more . . .

Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as… Read more . . .

Watson Pharmaceuticals has launched a generic levalbuterol inhalation solution, an authorized version of Sunovion’s Xopenex for the treatment of asthma. Shipments will begin immediately. The company cites IMS Health data saying that sales of Xopenex… Read more . . .

According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to… Read more . . .

GE Capital Healthcare Financial Services has announced today that it is providing $7.5 million in financing to Trimel Pharmaceuticals for Phase 2 and 3 clinical development of several OINDPs. Trimel’s pipeline includes asthma and allergic… Read more . . .

Israeli biopharmaceutical company Kamada will receive milestone payments of $60 million as part of a 12-year distribution agreement with Chiesi Farmaceutici for Kamada’s inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH). Chiesi… Read more . . .

According to Insmed, the US Patent and Trademark Office has issued the company a second composition of matter patent for Arikace liposomal amikacin for inhalation, US Patent No. 8,226,975. Insmed is developing the product for… Read more . . .

Aptar Pharma has announced that the Zetonna nasal aerosol device recently launched in the US includes a customized Aptar Landmark dose indicator, the result of a six-year collaboration with Sunovion. Zetonna is delivered by a… Read more . . .